New pill for chronic hives enters first human safety tests
NCT ID NCT07540910
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests the safety of an experimental oral drug called EDP-978 in 98 healthy adults. Researchers will give single and multiple doses to see how the body handles it and whether it causes side effects. The drug is being developed for chronic hives, but this study does not test if it works—only if it is safe enough to study further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EDP-978
- What this could lead to
- If safe, this could lead to larger trials testing EDP-978 as a treatment for chronic hives.
- What could go wrong
- This is a very early, small study in healthy people, not patients. It only checks safety and dosing, not whether the drug works for hives.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INDUCIBLE URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON Early Phase
RECRUITINGSan Antonio, Texas, 78209, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a diet tame chronic hives in teens?
- Can a new pill silence the itch of chronic hives?
- New drug aims to quiet chronic hives
- New pill for chronic hives enters first human tests
- New pill for chronic hives tested in everyday clinics
- New hope for chronic hive sufferers: phase 3 drug trial shows promise